An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque Psoriasis Receiving Two Weeks of Treatment
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- Sponsors Sun Pharmaceutical Industries
- 02 Nov 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 02 Nov 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated